| Dr Jeffrey Scott Hall, MD | |
|
1700 Altus St, Conway, AR 72032-4289 | |
| (501) 513-5909 | |
| (501) 513-5257 |
| Full Name | Dr Jeffrey Scott Hall |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 1700 Altus St, Conway, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134354293 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | E7933 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Conway Regional Health System | Conway, AR | Hospital |
| Ozark Health | Clinton, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Conway Regional Medical Center Inc | 3173428414 | 127 |
News Archive
If the Republics go ahead with the plan to repeal Obamacare, around 32 million Americans would lose their health cover according to a prediction from the Congressional Budget Office (CBO) yesterday. CBO is a non-partisan office that works to analyse pending bills and legislations.
In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.
Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn's disease, suggest the results of a phase I/II trial.
Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its fourth quarter and fiscal year 2012, which ended June 30, 2012.
Cochlear Limited, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Cochlear™ Nucleus® 6 Sound Processor for use with the Nucleus 22 Cochlear Implant, giving those who have worn cochlear implants from the beginning (over 20 years in some cases) access to the latest breakthroughs in true wireless and automatic hearing. Released in 1985, the Nucleus 22 Implant was the first commercially available multi-channel cochlear implant in the world.
› Verified 7 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841200417 PECOS PAC ID: 3173428414 Enrollment ID: O20040605000199 |
News Archive
If the Republics go ahead with the plan to repeal Obamacare, around 32 million Americans would lose their health cover according to a prediction from the Congressional Budget Office (CBO) yesterday. CBO is a non-partisan office that works to analyse pending bills and legislations.
In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.
Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn's disease, suggest the results of a phase I/II trial.
Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its fourth quarter and fiscal year 2012, which ended June 30, 2012.
Cochlear Limited, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Cochlear™ Nucleus® 6 Sound Processor for use with the Nucleus 22 Cochlear Implant, giving those who have worn cochlear implants from the beginning (over 20 years in some cases) access to the latest breakthroughs in true wireless and automatic hearing. Released in 1985, the Nucleus 22 Implant was the first commercially available multi-channel cochlear implant in the world.
› Verified 7 days ago
| Entity Name | Conway Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396913976 PECOS PAC ID: 3173428414 Enrollment ID: O20080404000463 |
News Archive
If the Republics go ahead with the plan to repeal Obamacare, around 32 million Americans would lose their health cover according to a prediction from the Congressional Budget Office (CBO) yesterday. CBO is a non-partisan office that works to analyse pending bills and legislations.
In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.
Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn's disease, suggest the results of a phase I/II trial.
Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its fourth quarter and fiscal year 2012, which ended June 30, 2012.
Cochlear Limited, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Cochlear™ Nucleus® 6 Sound Processor for use with the Nucleus 22 Cochlear Implant, giving those who have worn cochlear implants from the beginning (over 20 years in some cases) access to the latest breakthroughs in true wireless and automatic hearing. Released in 1985, the Nucleus 22 Implant was the first commercially available multi-channel cochlear implant in the world.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Scott Hall, MD 3507 West 4th Street, Little Rock, AR 72205-5710 Ph: () - | Dr Jeffrey Scott Hall, MD 1700 Altus St, Conway, AR 72032-4289 Ph: (501) 513-5909 |
News Archive
If the Republics go ahead with the plan to repeal Obamacare, around 32 million Americans would lose their health cover according to a prediction from the Congressional Budget Office (CBO) yesterday. CBO is a non-partisan office that works to analyse pending bills and legislations.
In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.
Expanded allogenic adipose-derived stem cells are effective for the treatment of perianal fistula in patients with Crohn's disease, suggest the results of a phase I/II trial.
Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its fourth quarter and fiscal year 2012, which ended June 30, 2012.
Cochlear Limited, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Cochlear™ Nucleus® 6 Sound Processor for use with the Nucleus 22 Cochlear Implant, giving those who have worn cochlear implants from the beginning (over 20 years in some cases) access to the latest breakthroughs in true wireless and automatic hearing. Released in 1985, the Nucleus 22 Implant was the first commercially available multi-channel cochlear implant in the world.
› Verified 7 days ago
Brandon M Thurow, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2869 College Ave, Conway, AR 72034 Phone: 501-327-2611 Fax: 501-336-9763 | |
Joe C Cummins, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2425 Dave Ward Dr, Suite 401, Conway, AR 72034 Phone: 501-329-3824 Fax: 501-327-2957 | |
Steven A James, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Altus St, Conway, AR 72032 Phone: 501-513-5909 Fax: 501-513-5257 | |
Bill Brooks Lawrence, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3650 College Ave, Conway, AR 72034 Phone: 501-327-6900 Fax: 501-327-3690 | |
Laura Massey, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 437 Denison St, Conway, AR 72034 Phone: 501-327-1325 Fax: 501-327-1328 | |
Dr. Clint Thurmond Seymour, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7 Winding Creek Cv, Conway, AR 72034 Phone: 864-980-2970 Fax: 501-222-6741 |